No Data
Immunotech Biopharm Ltd's (HKG:6978) Largest Shareholder, Top Key Executive Zheng Tan Sees Holdings Value Fall by 18% Following Recent Drop
IMMUNOTECH-B: POSTPONEMENT OF BOARD MEETING
IMMUNOTECH-B (06978.HK) plans to hold a Board of Directors meeting on March 28 to approve the annual performance.
Gelonghui reported on March 13 that IMMUNOTECH-B (06978.HK) announced that the company plans to hold a Board of Directors meeting on March 28, 2025 (Friday) to consider and approve (including) the annual performance and its release for the year ended December 31, 2024.
IMMUNOTECH-B (06978) has not yet submitted any new drug application for EAL and plans to submit it in the near future.
IMMUNOTECH-B (06978) issued an announcement stating that based on the recent cooperation with the National Medical Products Administration of China (NMP...
Express News | Immunotech Biopharm - Center for Drug Evaluation Agreed Group May Submit Application for Conditional Approval for Core Product Candidate, Eal
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
